ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1615

Evidence for Distinct Roles of Environmental and Genetic Factors in the Emergence of Anti Citrullinated-Protein Antibodies Positive Rheumatoid Arthritis-an Epidemiological Investigation in Twins

Aase Haj Hensvold1, Patrik KE Magnusson2, Monika Hansson3, Lena Israelsson4, Cecilia Carlens1, Johan Askling5, Vivianne Malmström6, Lars Klareskog7 and Anca Catrina1, 1Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 2Medical Epidemiology and Biostatistics, Swedish Twin Registry Karolinska Institutet, Stockholm, Sweden, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Sweden, 5Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, 6Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 7Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, genomics and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:  The aim of the current study was to investigate the influence of genetic and environmental factors in developing anti citrullianted-proteins antibodies (ACPA) and ACPA positive rheumatoid arthritis (RA), using a twin study approach.

Methods: We used a subset of the Swedish population based twin registry, which includes 12 590 monozygotic (MZ) and dizygotic (DZ) twins born 1958 or earlier, who had donated blood and provided information about smoking. RA was verified by data from national public care registers (1964-2009). All sera were analyzed for ACPA occurrence using a CCP2 ELISA  with a cut off set to 25 U/ml. High titer of ACPA was defined as titers >75 U/ml. Twin concordance for ACPA occurrence was estimated by casewise concordance, tetrachoric correlation and odds ratios (OR). Odd ratios (OR) to develop ACPA and high titers of ACPA were calculated according to self-reported smoking status, cumulative dose of smoking and presence of any HLA_DRB1 shared epitope according to GWAS analysis. Twins were defined as smokers if they were or had been smoking regularly or occasionally. Cumulative dose of smoking was estimated by pack years.

Results: 350 out of 12590 tested individuals (2.8%) were positive for ACPA with 202 out of 12590 tested individuals (1.6%) having high titers of ACPA (>75 U/ml). 192 out of 12590 tested individuals  were identified as having RA  in the Swedish patient register during 1964-2009. The median age of the RA patients was 70 (range 53-94) and 73% were females. Monozygotic twins had an OR of 3.1 (95% CI 0.9-10) for developing ACPA, 7.9 (95% CI 1.7-37) for developing high titers of ACPA and 11.6 (95% CI 1.27-98.6) for developing ACPA+ RA if they had a co-twin with corresponding phenotype. Dizygotic twins had lower OR for developing ACPA (OR 1.8, 95% CI 0.5-5.8), high titers of ACPA (OR 3.6, 95% CI 0.8-16) and ACPA+ RA (OR 4.0, 95% CI 0.5-31.1) if they had a co-twin with corresponding phenotype. Smokers had an increased risk of developing ACPA (OR 1.33, 95% CI 1.08-1.63), high titer of ACPA (OR 1.63, 95% CI 1.22-2.18) and high titer ACPA+ without RA (OR 1.99, 95% CI 1.27-3.12) but not significantly increased OR for ACPA+ RA (OR 1.42, 95% CI 0.98-2.06). An increased cumulative dose of smoking was associated with ACPA, with the highest risk of developing ACPA among those smoking more than 10 pack years (OR 1.49, 95% 1.18-1.88). Presence of shared epitope conferred an increased risk of developing ACPA (OR 1.98, 95% 1.53-2.56), high titer ACPA (OR 3.12, 95% 2.15-4.54) and especially high titer ACPA+ RA (OR 7.09, 95% 3.69-13.65) with no significantly increased OR to develop high titer ACPA+ without RA (OR 1.17, 95% 0.81-1.69).

Conclusion: Results from this large population-based cohort of middle-aged twins and measurements of ACPA at one time point indicate that environment, life style and stochastic factors (such as smoking) may be more important than genetics in determining which individuals that develop ACPA, whereas genetic factors (and in particular shared epitope) may have a larger impact in determining which persisting ACPA-positive individuals that will ultimately develop arthritis.


Disclosure:

A. Haj Hensvold,
None;

P. K. Magnusson,
None;

M. Hansson,
None;

L. Israelsson,
None;

C. Carlens,
None;

J. Askling,
None;

V. Malmström,
None;

L. Klareskog,
None;

A. Catrina,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-for-distinct-roles-of-environmental-and-genetic-factors-in-the-emergence-of-anti-citrullinated-protein-antibodies-positive-rheumatoid-arthritis-an-epidemiological-investigation-in-twins/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology